# TriLink BioTechnologies Analytical Services

Analytical testing is a critical component of every manufacturing program. As a CDMO with an ISO 9001:2015 certification and ICH Q7 Section 19 compliant quality system, we understand that successful biotherapeutic development and manufacturing are supported by comprehensive testing. We offer unparalleled expertise in phase-appropriate method development and analytical testing to further support your mRNA, plasmid, small molecule and oligonucleotide manufacturing process.

# Accelerate Your Product Development with Optimized Testing Services

With over 20 years of experience, we understand your analytical objectives from process development (PD) to scale-up and cGMP manufacturing. TriLink has developed extensive capabilities in custom method development and analytical testing to ensure a high quality manufacturing process. We work with you to ensure effective method development that meets your objectives at each stage of product development.



#### **Plasmid**

### Active Moiety Quantification:

• Concentration and Purity (UV Spec), % Supercoiled

#### Identification:

• Sequencing, Restriction Digest Pattern

# Safety (Microbial):

• Endotoxin, Bioburden

# Impurity Quantification:

• Residual Protein, Residual gDNA, Isoform Analysis & % RNA (HPLC)

# **Product Characterization:**

Appearance



# Oligonucleotide

# Active Moiety Quantification:

HPLC, Concentration (UV-Vis)

#### Identification:

• MS, Retention Time

#### Purity:

• IP-RP HPLC, AX-HPLC

# Safety (Microbial):

• Endotoxin, Bioburden

# Impurity Quantification:

• Residual Solvents, ICP-MS

# **Product Characterization:**

• Karl Fischer, Thermal Properties [Solution], NMR, Dynamic Vapor Sorption [Lyophilized]



#### **mRNA**

# Active Moiety Quantification:

Concentration

#### Identification:

• Sanger Sequencing, PCR, Length, In Vitro Translation, RNase Digestion, Analytical Transcription

#### Safety (Microbial):

• Endotoxin, Bioburden, Mycoplasma

# Impurity Quantification:

• Residual Protein, Residual DNA, Residual Solvents

#### Qualitative Assessment:

• Residual dsRNA, Residual Protein, Agarose Gel, DNase and RNase Detection

#### **Product Characterization:**

• Appearance, pH, Osmolality, Conductivity, Poly A Tail Length, Capping Efficiency, Integrity



# NTPs, CleanCap® and Other Cap Analogs

#### Active Moiety Quantification:

• Concentration (UV-Vis)

### Identification:

MS, <sup>1</sup>H NMR

# Purity:

• IP-RP HPLC, AX-HPLC, 31P NMR

# Safety (Microbial):

• Endotoxin, Bioburden

# Qualitative Assessment:

• DNase and RNase Detection, Transcription Functional Test

# **Product Characterization:**

• Conductivity, pH

Products containing CleanCap technology are for research use only. License is required for commercial use of CleanCap and CleanCap Products. For license restrictions and patent(s) information, refer to https://www.trilinkbiotech.com/legal-notices



